- Molecular NameTacrine
- SynonymTetrahydroaminacrine; Tetrahydroaminoacridine; Tetrahydroaminocrin; Tetrahydroaminocrine; THA
- Weight198.269
- Drugbank_IDDB00382
- ACS_NO321-64-2
- Show 2D model
- LogP (experiment)2.71
- LogP (predicted, AB/LogP v2.0)2.69
- pka9.95
- LogD (pH=7, predicted)-0.18
- Solubility (experiment)0.217 mg/ml
- LogS (predicted, ACD/Labs)(ph=7)-1.35
- LogSw (predicted, AB/LogsW2.0)0.04
- Sw (mg/ml) (predicted, ACD/Labs)0.07
- No.of HBond Donors2
- No.of HBond Acceptors2
- No.of Rotatable Bonds0
- TPSA38.91
- StatusFDA approved
- AdministrationOral, rectal
- PharmacologyA parasympathomimetic and a centrally acting cholinesterase inhibitor (anticholinesterase). It was the first centrally-acting cholinesterase inhibitor approved for the treatment of Alzheimer's disease, and was marketed under the trade name Cognex.
- Absorption_value95.0
- Absorption (description)Tacrine is rapidly absorbed. Absolute bioavailability of tacrine is approximately 17 ± 13%
- Caco_2N/A
- Bioavailability17.0
- Protein binding55.0
- Volume of distribution (VD)8.22 L/kg
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmHepatic. Cytochrome P450 1A2 is the principal isozyme involved in tacrine metabolism. The major metabolite, 1-hydroxy-tacrine (velnacrine), has central cholinergic activity.
- Half life1.5 to 2 h.
- ExcretionRenal
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityOverdosage with cholinesterase inhibitors can cause a cholinergic crisis characterized by severe nausea/vomiting, salivation, sweating, bradycardia, hypotension, collapse, and convulsions. Increasing muscle weakness is a possibility and may result in death if respiratory muscles are involved. The estimated median lethal dose of tacrine following a single oral dose in rats is 40 mg/kg, or approximately 12 times the maximum recommended human dose of 160 mg/day.
- LD50 (rat)N/A
- LD50 (mouse)LD50=39.8 (peroral)